6 studies found for:    10685652 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental;   Experimental Melanomas
Interventions: Biological: aldesleukin;   Biological: therapeutic autologous lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine phosphate;   Radiation: Total body irradiation
2 Recruiting Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Conditions: Metastatic Cancer;   Melanoma
Interventions: Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
3 Recruiting Study of Cell Transfer Therapy for Metastatic Melanoma Using 4-1BB Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy
Conditions: Melanoma;   Skin Cancer
Interventions: Drug: Interleukin-2;   Drug: Fludarabine;   Drug: Cylcophosphamide;   Genetic: 41BB Selected Tumor Infiltrating Lymphocytes
4 Active, not recruiting Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI
Conditions: Metastatic Melanoma;   Skin Cancer
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
5 Completed
Has Results
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Conditions: Skin Cancer;   Metastatic Melanoma
Intervention: Drug: Aldesleukin
6 Completed
Has Results
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Conditions: Skin Cancer;   Melanoma;   Metastatic Melanoma
Interventions: Biological: Aldesleukin;   Biological: CD8 enriched Young TIL

Indicates status has not been verified in more than two years